Endurant Capital Management LP Albireo Pharma, Inc. Transaction History

Endurant Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$18.01 - $23.78 $803,029 - $1.06 Million	44,588 Added 25.83%	217,209 $4.69 Million
Q3 2022 Nov 14, 2022	BUY	$16.32 - $26.37 $2.2 Million - $3.55 Million	134,786 Added 356.25%	172,621 $3.34 Million
Q2 2022 Aug 15, 2022	SELL	$18.54 - $37.29 $1.54 Million - $3.1 Million	-82,999 Reduced 68.69%	37,835 $751,000
Q1 2022 May 16, 2022	BUY	$23.94 - $33.74 $1.32 Million - $1.86 Million	55,196 Added 84.09%	120,834 $3.6 Million
Q4 2021 Feb 14, 2022	SELL	$21.19 - $31.29 $1.1 Million - $1.62 Million	-51,690 Reduced 44.06%	65,638 $1.53 Million
Q3 2021 Nov 15, 2021	BUY	$27.36 - $35.98 $378,005 - $497,099	13,816 Added 13.35%	117,328 $3.66 Million
Q2 2021 Aug 16, 2021	BUY	$28.9 - $36.87 $9,739 - $12,425	337 Added 0.33%	103,512 $3.64 Million
Q1 2021 May 17, 2021	BUY	$32.03 - $42.85 $1.95 Million - $2.61 Million	60,883 Added 143.96%	103,175 $3.64 Million
Q4 2020 Feb 16, 2021	SELL	$31.56 - $42.16 $310,518 - $414,812	-9,839 Reduced 18.87%	42,292 $1.59 Million
Q3 2020 Nov 16, 2020	BUY	$23.19 - $41.61 $1.21 Million - $2.17 Million	52,131 New	52,131 $1.74 Million

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.